Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)
Conditions:
Acute Myeloid Leukemia (AML)
Sponsor: Technische Universität Dresden
trial.available_in:
БГ
Overview
This is a registry study in adult patients with newly diagnosed or refractory/relapsed acute myeloid leukemia.
Investigator's sites: 60 sites in Germany.
Primary objectives:
* Identification of epidemiological data on AML: age, prognostic factors and subgroup distributions. Incidence and age distribution are compared with the data of population-related tumor registry.
* Evaluation of the most important patient-relevant clinical endpoints (outcomes): relapse-free survival (RFS) / time to relapse (TTR), calculation of cumulative incidence of relapse (CIR) and overall survival (OS)
* Documentation of treatment strategy
Description
see brief summary
Who can participate
Inclusion Criteria:
* AML according to the WHO (World Health Organization) diagnostic criteria, including acute promyelocytic leukemia
* Age ≥ 18 years. There is no upper age limit.
* Signed written informed consent
Exclusion Criteria:
* there are no exclusion criteria
Locations
60
Germany (60)
Universitätsklinikum Aachen
Aachen , North Rhine-Westphalia
Klinikum Altenburger Land GmbH
Altenburg , Thuringia
Klinikum Augsburg
Augsburg , Bavaria
Klinikum Mittelbaden
Baden-Baden , Baden-Wurttemberg
Sozialstiftung Bamberg
Bamberg , Bavaria
Klinikum Bayreuth GmbH
Bayreuth , Bavaria
Alexianer St. Hedwig-Krankenhaus
Berlin , State of Berlin
Helios Klinikum Berlin-Buch
Berlin , State of Berlin
Städt. Kliniken Bielefeld gem. GmbH - Klinikum Mitte
БГ